Kenvue (KVUE) Projected to Post Earnings on Thursday

Kenvue (NYSE:KVUE - Get Free Report) is expected to be announcing its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $3.79 billion for the quarter. Kenvue has set its FY 2024 guidance at 1.100-1.200 EPS and its FY24 guidance at $1.10-1.20 EPS.Persons that are interested in participating in the company's earnings conference call can do so using this link.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business's revenue was down .4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.31 earnings per share. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Up 1.9 %

Shares of NYSE KVUE traded up $0.41 during midday trading on Thursday, hitting $21.72. The stock had a trading volume of 11,733,016 shares, compared to its average volume of 11,519,469. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a market cap of $41.64 billion, a P/E ratio of 39.48, a PEG ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business's 50 day moving average is $22.00 and its 200-day moving average is $21.85.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.78%. Kenvue's dividend payout ratio is currently 149.09%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler upgraded shares of Kenvue from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $21.00 to $26.00 in a research report on Monday, January 6th. Bank of America upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research report on Friday, January 17th. Finally, Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Kenvue currently has a consensus rating of "Hold" and an average target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.